Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome

Neurourology and Urodynamics

Volumn 28, Issue 1, 2009, Pages 47-51

  Tseng, Ling Hong ^a   Wang, Alex C ^a   Chang, Yao Lung ^a   Soong, Yung Kuei ^a   Lloyd, L Keith ^b   Ko, Yet Jane ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Antimuscarinics; Menopause; Overactive bladder syndrome; Vaginal estrogen cream

Indexed keywords

CONJUGATED ESTROGEN; PREMARIN VAGINAL CREAM; TOLTERODINE; UNCLASSIFIED DRUG; AGENTS USED INTRAVAGINALLY; BENZHYDRYL DERIVATIVE; CRESOL; ESTROGEN; MUSCARINIC RECEPTOR BLOCKING AGENT; PHENYLPROPANOLAMINE;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NOCTURIA; OVERACTIVE BLADDER; POSTMENOPAUSE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; URGE INCONTINENCE; URINARY FREQUENCY; URINARY URGENCY; URINE RETENTION; URINE VOLUME; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; INTRAVAGINAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; SYNDROME; TIME; TREATMENT OUTCOME; URODYNAMICS;

ADMINISTRATION, INTRAVAGINAL; AGED; BENZHYDRYL COMPOUNDS; CRESOLS; DRUG THERAPY, COMBINATION; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; POSTMENOPAUSE; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; SYNDROME; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URODYNAMICS; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 59449097072     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.20583     Document Type: Article

References (26)

1. Chen GD, Lin TL, Hu SW, et al. Prevalence and correlation of urinary incontinence and overactive bladder in Taiwanese women. Neurourol Urodyn 2003;22:109-17.
2. Oulander JG. Management of overactive bladder. N Engl J Med 2004;350: 786-99.
3. Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol 2004;3:46-53.
4. Alhasso AA, Mckinlay J, Patrick K, et al. Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006;4: CD003193.
5. Kay GG, Granville LJ. Antimuscarinic agents: Implications and concerns in the management of overactive bladder in the elderly. Clin Ther 2005;27: 127-38.
6. Jackson S, James M, Abrams P. The effect of oestradiol on vaginal collagen metabolismin postmenopausal womenwith genuine stress incontinence. Br J Obstet Gynaecol 2002;109:339-44.
7. Enzelsberger H, Kurz C, Schatten C, et al. The effectiveness of intravaginal estriol tablet administration in women with urge incontinence. Frauenheilkunde 1991;51:834-8.
8. Eriksen PS, Rasmussen H. Low-dose 17 beta-estradiol vaginal tablets in the treatment of atrophic vaginitis: A double-blind placebo controlled study. Eur J Obst Gyn 1992;44:137-44.
9. Cardozo LD, Wise BG, Benness CJ. Vaginal oestradiol for the treatment of lower urinary tract symptoms in postmenopausal women-A double-blind placebo-controlled study. J Obst Gyn 2001;21:383-5.
10. Grady D, Brown JS, Vittinghoff E, et al. Postmenopausal hormones and incontinence: The Heart and Estrogen/Progestin Replacement Study. Obstet Gynecol 2001;97:116-20.
11. Robimson D, Cardozo LD. The role of estrogens in female lower urinary tract dysfunction. Urology 2003;62:45-51.
12. Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc 2002;50:799-807.
13. Millard RJ. Asia Pacific Tolterodine Study Group. Clinical efficacy of tolterodine with or without a simplified pelvic floor exercise regimen. Neurourol Urodyn 2004;23:48-53.
14. Zullo MA, Plotti F, Calcagno M, et al. Vaginal estrogen therapy and overactive bladder symptoms in postmenopausal patients after a tension-free vaginal tape procedure: A randomized clinical trial. Menopause 2005;12: 421-7.
15. Long CY, Liu CM, Hsu SC, et al. A randomized comparative study of the effects of oral and topical estrogen therapy on the lower urinary tract of hysterectomized postmenopausal women. Fertil Steril 2006;85:155-60.
16. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: Report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn 2002; 21:167-78.
17. Bump RC, Mattiasson A, Bo K, et al. The standardization of terminology of female organ prolapse and pelvic floor dysfunction. Am J Obstet Gynecol 1996;175:10-7.
18. Milleman M, Langenstroer P, Guraknick ML. Post-void residual urine volume in women with overactive bladder symptoms. J Urol 2004;172:1911-4.
19. Snedecor WG, Cochran GW. 1980. Statistical methods. 7th edition. Ames: Iowa State University Press; pp 129-30.
20. Michel MC, Schneider T, Krege S, et al. Does gender or age affect the efficacy and safety of tolterodine? J Urol 2002;168:1027-31.
21. Poller U, Nedelka G, Radke J, et al. Age-dependent changes in cardiac muscarinic receptor function in healthy volunteers. J Am Coll Cardiol 1997; 29:187-93.
22. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760-66.
23. Schmidbauer J, Temml C, Schatzl G, et al. Risk factors for urinary incontinence in both sexes. Analysis of a health screening project. Eur Urol 2001;39:565-70.
24. Hextall A. Oestrogens and lower urinary tract function. Maturitas 2000;36: 83-92.
25. Matza LS, Tompson CL, Krasnow J, et al. Test-retest reliability of four questionnaires for patients with overactive bladder: The overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). Neurourol Urodyn 2005;24:215-25.
26. Malone-Lee J, Shaffu B, Anand C, et al. Tolterodine: Superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J Urol 2001; 165:1452-6.